Drug Patents Expiring in 2022

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

CN103288727A OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882A OTSUKA Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof
Sep, 2022

(8 days ago)

CN103288727B OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882B OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B1 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A3 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A2 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308A1 OTSUKA Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A3 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356A1 OTSUKA Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B2 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355A1 OTSUKA Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A2 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A8 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A9 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308B1 OTSUKA Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution Oct, 2022

(20 days from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
15MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

2. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

CN103288727A OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882A OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof
Sep, 2022

(8 days ago)

CN103288727B OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882B OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355B1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A3 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A2 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308A1 OTSUKA PHARM CO LTD Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A3 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356A1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B2 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355A1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356B1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A2 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A8 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A9 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308B1 OTSUKA PHARM CO LTD Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357B1 OTSUKA PHARM CO LTD Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(8 days ago)

CN103288727A OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882A OTSUKA Low Hygroscopic Aripiprazole Medicine And Preparation Method Thereof
Sep, 2022

(8 days ago)

CN103288727B OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

CN1817882B OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B1 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A3 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A2 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308A1 OTSUKA Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A3 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356A1 OTSUKA Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776B2 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927355A1 OTSUKA Low Hygroscopic Aripiprazole (Crystal F) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927356B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal D) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357A2 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A8 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1419776A9 OTSUKA Low Hygroscopic Aripiprazole Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1925308B1 OTSUKA Pharmaceutical Solid Oral Aripiprazole Preparation And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

EP1927357B1 OTSUKA Low Hygroscopic Aripiprazole (Crystal E) Drug Substance And Processes For The Preparation Thereof
Sep, 2022

(8 days ago)

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

4. Drug name - ADDYI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7420057 SPROUT PHARMS Stable polymorph of flibanserin
Aug, 2022

(2 months ago)

IN226632B SPROUT PHARMS Crystalline Polymorph A (Form A) Of Flibanserin 1 And Process For Preparing The Same
Jul, 2022

(2 months ago)

IN200302139P1 SPROUT PHARMS Crystalline Polymorph A (Form A) Of Flibanserin 1 And Process For Preparing The Same
Jul, 2022

(2 months ago)

EP1414816B1 SPROUT PHARMS Stable Polymorph Of Flibanserin, Technical Process For Its Preparation And The Use Thereof For Preparing Medicaments
Jul, 2022

(2 months ago)

EP1414816A1 SPROUT PHARMS Stable Polymorph Of Flibanserin, Technical Process For Its Preparation And The Use Thereof For Preparing Medicaments
Jul, 2022

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468639 SPROUT PHARMS Treating sexual desire disorders with flibanserin Oct, 2022

(12 days from now)

Drugs and Companies using FLIBANSERIN ingredient

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

5. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097653 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation Nov, 2022

(a month from now)

US8389542 SUCAMPO PHARMA LLC Dosage unit comprising a prostaglandin analog for treating constipation Nov, 2022

(a month from now)

US6982283 SUCAMPO PHARMA LLC Method for treating drug-induced constipation Dec, 2022

(2 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

6. Drug name - AMLODIPINE BESYLATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6828339 SYNTHON PHARMS Amlodipine salt forms and processes for preparing them
Nov, 2022

(a month from now)

Drugs and Companies using AMLODIPINE BESYLATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
EQ 5MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
EQ 10MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

7. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8512727 BAUDAX Nanoparticulate meloxicam formulations Dec, 2022

(2 months from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

8. Drug name - AVANDAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236345 SB PHARMCO Composition and use Oct, 2022

(3 days from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 2MG BASE TABLET;ORAL Discontinued
1GM;EQ 4MG BASE TABLET;ORAL Discontinued
500MG;EQ 1MG BASE TABLET;ORAL Discontinued
500MG;EQ 2MG BASE TABLET;ORAL Discontinued
500MG;EQ 4MG BASE TABLET;ORAL Discontinued

9. Drug name - BANZEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(a month from now)

EP994863B1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

EP994863A1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

Drugs and Companies using RUFINAMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Discontinued
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription

10. Drug name - BEYAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG TABLET;ORAL Prescription

11. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Oct, 2022

(5 days from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

12. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Oct, 2022

(5 days from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

13. Drug name - BYLVAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416 ALBIREO Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(28 days ago)

IN200400539P1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia
Sep, 2022

(28 days ago)

IN248635B ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Lleal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Of Hyperlipidaemia
Sep, 2022

(28 days ago)

EP1427423A1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(28 days ago)

EP1427423B9 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(28 days ago)

EP1427423B1 ALBIREO Benzothiazepine And Benzothiadiazepine Derivatives With Ileal Bile Acid Transport (Ibat) Inhibitory Activity For The Treatment Hyperlipidaemia
Sep, 2022

(28 days ago)

Drugs and Companies using ODEVIXIBAT ingredient

Treatment: NA

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.2MG CAPSULE, PELLETS;ORAL Prescription
0.6MG CAPSULE, PELLETS;ORAL Prescription
0.4MG CAPSULE;ORAL Prescription
1.2MG CAPSULE;ORAL Prescription

14. Drug name - CAPRELSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(3 months ago)

Drugs and Companies using VANDETANIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

15. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(5 months ago)

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

16. Drug name - CHANTIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(4 months ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(2 months ago)

CN100370987C PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate
Apr, 2022

(5 months ago)

CN1509174A PF PRISM CV 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0
Apr, 2022

(5 months ago)

IN204091B PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

IN200300863P3 PF PRISM CV Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307A1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

EP1392307B1 PF PRISM CV Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene
Apr, 2022

(5 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof Nov, 2022

(a month from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

17. Drug name - COMBIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7642258 ALLERGAN Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(5 months ago)

CN112219061A ALLERGAN Suspension Type Vertical Decoration Light Guide Lamp With Sound Suppression
Jan, 2022

(8 months ago)

More Information on Dosage
Strength Dosage Availability
0.2%;EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

18. Drug name - DORYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161 MAYNE PHARMA Modified release coated drug preparation Dec, 2022

(2 months from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, DELAYED RELEASE;ORAL Prescription
EQ 60MG BASE TABLET, DELAYED RELEASE;ORAL Discontinued
EQ 120MG BASE TABLET, DELAYED RELEASE;ORAL Prescription

19. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(17 days from now)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(17 days from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

20. Drug name - EPIDIOLEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10195159 GW RES LTD Processes and apparatus for extraction of active substances and enriched extracts from natural products
May, 2022

(4 months ago)

EP1385595A2 GW RES LTD Processes For Preparing A Cannabinoid-Rich Extract From Cannabis Plant Material
May, 2022

(4 months ago)

EP1385595B1 GW RES LTD Processes For Preparing A Cannabinoid-Rich Extract From Cannabis Plant Material
May, 2022

(4 months ago)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SOLUTION;ORAL Prescription

21. Drug name - EPIDUO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241649 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide Dec, 2022

(2 months from now)

US8936800 GALDERMA LABS LP Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Dec, 2022

(2 months from now)

US8105618 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide Dec, 2022

(2 months from now)

US8809305 GALDERMA LABS LP Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris Dec, 2022

(2 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1%;2.5% GEL;TOPICAL Prescription

22. Drug name - EPIDUO FORTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785420 GALDERMA LABS Combination/association of adapalene and benzoyl peroxide for treating acne lesions Dec, 2022

(2 months from now)

US8936800 GALDERMA LABS Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Dec, 2022

(2 months from now)

US8445543 GALDERMA LABS Combinations of adapalene and benzoyl peroxide for treating acne lesions Dec, 2022

(2 months from now)

US8809305 GALDERMA LABS Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris Dec, 2022

(2 months from now)

US9814690 GALDERMA LABS Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Dec, 2022

(2 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3%;2.5% GEL;TOPICAL Prescription

23. Drug name - FOLOTYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071 ACROTECH Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(2 months ago)

Drugs and Companies using PRALATREXATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
20MG/ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
40MG/2ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

24. Drug name - FUSILEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6500829 ACROTECH Substantially pure diastereoisomers of tetrahydrofolate derivatives
Mar, 2022

(6 months ago)

Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued
EQ 250MG BASE/25ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

25. Drug name - FYCOMPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2022

(3 months ago)

Drugs and Companies using PERAMPANEL ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

26. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(8 months ago)

IN203882B ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Targe Gene
Jan, 2022

(8 months ago)

IN213846B ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300572P3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300537P3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B1 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B9 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061A2 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP2213736A3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736B1 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A2 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

27. Drug name - GRALISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252332 ALMATICA Gastric retained gabapentin dosage form Oct, 2022

(21 days from now)

US8192756 ALMATICA Gastric retained gabapentin dosage form Oct, 2022

(21 days from now)

US8333992 ALMATICA Gastric retained gabapentin dosage form Oct, 2022

(21 days from now)

US7731989 ALMATICA Gastric retained gabapentin dosage form Oct, 2022

(21 days from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription

28. Drug name - HALFLYTELY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291324 BRAINTREE Method of bowel cleansing Oct, 2022

(18 days from now)

Drugs and Companies using BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE ingredient

Treatment: Gastrointestinal lavage indicated for cleansing of the colon as a preparation for colonoscopy in adults

Dosage: FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL Discontinued

29. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(2 months from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

30. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(2 months from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

31. Drug name - HORIZANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917 ARBOR PHARMS LLC Prodrugs of GABA analogs, compositions and uses thereof
Nov, 2022

(a month from now)

CN101434572A ARBOR PHARMS LLC Prodrug Of Gaba Analogue, Composition And Application Thereof
Jun, 2022

(3 months ago)

CN101434572B ARBOR PHARMS LLC Prodrug Of Gaba Analogue, Composition And Application Thereof
Jun, 2022

(3 months ago)

EP1404324B1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324A4 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324B2 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324A2 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1902714B1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1902714A1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

32. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384649 ACORDA Particulate compositions for pulmonary delivery Nov, 2022

(a month from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

33. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(17 days from now)

US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(17 days from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

34. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

35. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

36. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

37. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

38. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(6 months ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(5 months ago)

IN203882B NOVARTIS Method For Inhibiting The Expression Of A Targe Gene
Jan, 2022

(8 months ago)

IN213846B NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300572P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300537P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B9 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP2213736A3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

39. Drug name - LEXAPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(a month ago)

CN1311819C ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

CN1536997A ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

IN227935B ALLERGAN A Method For Manufacture Of Crystalline Particles Of Escitalpram Oxalate
Jul, 2022

(2 months ago)

IN200400405P4 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

EP1414435B1 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

EP1414435A1 ALLERGAN Crystalline Composition Containing Escitalopram
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription

40. Drug name - LEXISCAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(5 months ago)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/5ML (0.08MG/ML) SOLUTION;INTRAVENOUS Prescription

41. Drug name - LUPKYNIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2022

(13 days from now)

CN100344648C AURINIA Cyclosporine Analogue Mixtures And Their Use In Preparation Of Immunomodulator
Oct, 2022

(13 days from now)

CN1571795A AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

CN100334106C AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

CN1274294C AURINIA Cyclosporin Analog Microemulsion Preconcentrates
Oct, 2022

(13 days from now)

CN1571657A AURINIA Novel Cyclosporin Analog Microemulsion Preconcentrates
Oct, 2022

(13 days from now)

CN1571794A AURINIA Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents
Oct, 2022

(13 days from now)

CN100497748C AURINIA Polishing Component And The Conductive Layer To Perform Electrolytic Polishing Method
Nov, 2022

(a month from now)

CN1585835A AURINIA Polishing Assembly And The Conductive Layer Is Subjected To Electrolytic Polishing Method
Nov, 2022

(a month from now)

IN200400693P1 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

IN201105103P1 AURINIA Method Of Producing An E-Isomer And A Z-Isomer
Oct, 2022

(13 days from now)

IN256418B AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

IN304347B AURINIA Method Of Producing An E-Isomer And A Z-Isomer
Oct, 2022

(13 days from now)

EP1436322B1 AURINIA Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents
Oct, 2022

(13 days from now)

EP1714977B1 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1436321B9 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1714977A2 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1436321B1 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1435910B1 AURINIA Novel Cyclosporin Analog Microemulsion Preconcentrates
Oct, 2022

(13 days from now)

EP1435910A1 AURINIA Novel Cyclosporin Analog Microemulsion Preconcentrates
Oct, 2022

(13 days from now)

EP1436322A2 AURINIA Cyclosporine Analogue Mixtures And Their Use As Immunomodulating Agents
Oct, 2022

(13 days from now)

EP1436321A2 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1714977A3 AURINIA Synthesis Of Cyclosporin Analogs
Oct, 2022

(13 days from now)

EP1435910B9 AURINIA Novel Cyclosporin Analog Microemulsion Preconcentrates
Oct, 2022

(13 days from now)

Drugs and Companies using VOCLOSPORIN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
7.9MG CAPSULE;ORAL Prescription

42. Drug name - LUSEDRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6204257 EISAI INC Water soluble prodrugs of hindered alcohols
Jul, 2022

(3 months ago)

Drugs and Companies using FOSPROPOFOL DISODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1050MG/30ML (35MG/ML) SOLUTION;INTRAVENOUS Discontinued

43. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(5 months ago)

Drugs and Companies using OLAPARIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

44. Drug name - MACRILEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(2 months ago)

Drugs and Companies using MACIMORELIN ACETATE ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE/POUCH FOR SOLUTION;ORAL Prescription

45. Drug name - MICARDIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system Oct, 2022

(2 days from now)

Drugs and Companies using TELMISARTAN ingredient

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

46. Drug name - MOVANTIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7662365 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(14 days from now)

EP1436012A2 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(14 days from now)

EP2939696A1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(14 days from now)

EP1436012B1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(14 days from now)

EP2939696B1 REDHILL Polymer Conjugates Of Opioid Antagonists
Oct, 2022

(14 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617530 REDHILL Polymer conjugates of opioid antagonists Oct, 2022

(14 days from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

47. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(6 months ago)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

48. Drug name - MYRBETRIQ GRANULES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(6 months ago)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

49. Drug name - NEURONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7256216

(Pediatric)

VIATRIS Liquid pharmaceutical compositions Nov, 2022

(a month from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
250MG/5ML SOLUTION;ORAL Prescription

50. Drug name - NUCYNTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(a month ago)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Discontinued

51. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156 COLLEGIUM PHARM INC Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol Oct, 2022

(18 days from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: Relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

52. Drug name - OCALIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7138390 INTERCEPT PHARMS INC Steroids as agonists for FXR
Nov, 2022

(a month from now)

EP1392714A1 INTERCEPT PHARMS INC Steroids As Agonists For Fxr
Feb, 2022

(7 months ago)

EP1392714B1 INTERCEPT PHARMS INC Steroids As Agonists For Fxr
Feb, 2022

(7 months ago)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

53. Drug name - OFORTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient Dec, 2022

(2 months from now)

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Discontinued

54. Drug name - OSPHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566252 DUCHESNAY Method for the alleviation of dyspareunia in women Nov, 2022

(29 days from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of dyspareunia associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

55. Drug name - PEPAXTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2022

(3 months ago)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Discontinued

56. Drug name - PRISTIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6673838 PF PRISM CV Succinate salt of O-desmethyl-venlafaxine
Mar, 2022

(7 months ago)

CN1501909A PF PRISM CV A New O-Demethyl-Venlafaxine Succinate
Feb, 2022

(7 months ago)

CN100567253C PF PRISM CV O-Desmethyl-Venlafaxine Succinate
Feb, 2022

(7 months ago)

IN200301015P2 PF PRISM CV Novel Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

IN201649B PF PRISM CV Novel Succinate Salt Of O-Desmethyl- Venlafaxine
Feb, 2022

(7 months ago)

EP1360169B2 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

EP1360169B1 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

EP1360169A2 PF PRISM CV Succinate Salt Of O-Desmethyl-Venlafaxine
Feb, 2022

(7 months ago)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

57. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(a month from now)

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID TABLET;ORAL Prescription
EQ 25MG ACID TABLET;ORAL Prescription
EQ 50MG ACID TABLET;ORAL Prescription
EQ 75MG ACID TABLET;ORAL Prescription
EQ 100MG ACID TABLET;ORAL Discontinued

58. Drug name - PROMACTA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7160870 NOVARTIS Thrombopoietin mimetics
Nov, 2022

(a month from now)

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG ACID/PACKET FOR SUSPENSION;ORAL Prescription
EQ 25MG ACID/PACKET FOR SUSPENSION;ORAL Prescription

59. Drug name - RYANODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110225 EAGLE PHARMS Treatment using dantrolene Dec, 2022

(2 months from now)

US8604072 EAGLE PHARMS Treatment using dantrolene Dec, 2022

(2 months from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL FOR SUSPENSION;INTRAVENOUS Prescription

60. Drug name - RYDAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity Oct, 2022

(25 days from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription

61. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

EP944648A1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648B1 NOVO Glp-1 Derivatives
Aug, 2022

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

62. Drug name - SELZENTRY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368460 VIIV HLTHCARE Tropane derivatives useful in therapy Nov, 2022

(a month from now)

Drugs and Companies using MARAVIROC ingredient

Treatment: Method of treating patients infected with ccr5-tropic hiv-1

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET;ORAL Prescription
75MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

63. Drug name - SINGULAIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830 MERCK Granule formation Oct, 2022

(20 days from now)

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/PACKET GRANULE;ORAL Prescription

64. Drug name - STEGLUJAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(2 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(2 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(2 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(2 months ago)

More Information on Dosage
Strength Dosage Availability
5MG;EQ 100MG BASE TABLET;ORAL Prescription
15MG;EQ 100MG BASE TABLET;ORAL Prescription

65. Drug name - STIVARGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(3 months ago)

EP1379507B1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

EP1379507A1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

66. Drug name - SUBOXONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285910 INDIVIOR INC Sublingual and buccal film compositions Oct, 2022

(7 days from now)

More Information on Dosage
Strength Dosage Availability
EQ 2MG BASE;EQ 0.5MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 4MG BASE;EQ 1MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 8MG BASE;EQ 2MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 12MG BASE;EQ 3MG BASE FILM;BUCCAL, SUBLINGUAL Prescription

67. Drug name - SUMAVEL DOSEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8343130 ENDO VENTURES LTD Needleless injector Oct, 2022

(14 days from now)

US8491524 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Nov, 2022

(a month from now)

US8241244 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof Nov, 2022

(a month from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued

68. Drug name - TEFLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6417175 ALLERGAN Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Apr, 2022

(5 months ago)

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/VIAL POWDER;INTRAVENOUS Prescription
600MG/VIAL POWDER;INTRAVENOUS Prescription

69. Drug name - TOBI PODHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside Dec, 2022

(2 months from now)

US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside Dec, 2022

(2 months from now)

US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides Dec, 2022

(2 months from now)

Drugs and Companies using TOBRAMYCIN ingredient

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
28MG POWDER;INHALATION Prescription

70. Drug name - TOVIAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(3 months ago)

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET, EXTENDED RELEASE;ORAL Prescription
8MG TABLET, EXTENDED RELEASE;ORAL Prescription

71. Drug name - TRI-LUMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247395 GALDERMA LABS LP Topical skin care composition Oct, 2022

(21 days from now)

US8653053 GALDERMA LABS LP Topical skin care composition Oct, 2022

(21 days from now)

More Information on Dosage
Strength Dosage Availability
0.01%;4%;0.05% CREAM;TOPICAL Prescription

72. Drug name - TRULANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(3 months ago)

CN103641892B SALIX Guanylate Cyclase Receptor Agonist For Treating Tissue Inflammation And Cancer
Mar, 2022

(6 months ago)

CN102643333B SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

CN102643333A SALIX Guanylate Cyclase Receptor Stimulant For Treating Tissue Inflammation And Canceration
Mar, 2022

(6 months ago)

CN103641892A SALIX For Treating Tissue Inflammation And Cancer Of Guanylate Cyclase Receptor Agonist
Mar, 2022

(6 months ago)

EP2103624B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2301952A2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2103624A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952A3 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A4 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

73. Drug name - VARUBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists Dec, 2022

(2 months from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) EMULSION;INTRAVENOUS Discontinued

74. Drug name - VELCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(8 months ago)

US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(8 months ago)

EP2251344A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP1355910A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP2251344B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP1355910B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP3078667B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP3078667A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL INJECTABLE;INTRAVENOUS, SUBCUTANEOUS Prescription

75. Drug name - VEREGEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10434059 ANI PHARMS Medicament for the treatment of viral skin and tumour diseases Nov, 2022

(a month from now)

Drugs and Companies using SINECATECHINS ingredient

Treatment: Treatment of genital warts

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% OINTMENT;TOPICAL Prescription

76. Drug name - VICTOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(a month ago)

EP944648A1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

EP944648B1 NOVO NORDISK INC Glp-1 Derivatives
Aug, 2022

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1 Dec, 2022

(2 months from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

77. Drug name - VIIBRYD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7834020 ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(3 months ago)

US8673921 ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Jun, 2022

(3 months ago)

CN100384841C ALLERGAN 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

CN101139345A ALLERGAN Polymorphic Forms Of 1-4-(5-Cyanoindol-3-Group) Butyl-4-(2-Carbamoylbenzofuran-5-Group) Piperazine Hydrochloride
Jun, 2022

(3 months ago)

CN1516699A ALLERGAN 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

CN101139345B ALLERGAN 1 - [4 - (5-Indole-3-Yl) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph
Jun, 2022

(3 months ago)

EP1397357B1 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

EP1397357A2 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

EP1397357B9 ALLERGAN Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride
Jun, 2022

(3 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673921

(Pediatric)

ALLERGAN Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

US7834020

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

US8193195

(Pediatric)

ALLERGAN Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Dec, 2022

(2 months from now)

US8236804

(Pediatric)

ALLERGAN Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Dec, 2022

(2 months from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

78. Drug name - VIMPAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551 UCB INC Anticonvulsant enantiomeric amino acid derivatives
Mar, 2022

(6 months ago)

EP888289A1 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2022

(6 months ago)

EP888289B1 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2022

(6 months ago)

Drugs and Companies using LACOSAMIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

79. Drug name - WELCHOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229613

(Pediatric)

DAIICHI SANKYO Method for lowering serum glucose Oct, 2022

(13 days from now)

More Information on Dosage
Strength Dosage Availability
1.875GM/PACKET FOR SUSPENSION;ORAL Discontinued
3.75GM/PACKET FOR SUSPENSION;ORAL Prescription

80. Drug name - XERESE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester Nov, 2022

(a month from now)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
5%;1% CREAM;TOPICAL Prescription

81. Drug name - XOFIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning Nov, 2022

(a month from now)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
162mCi/6ML (27mCi/ML) SOLUTION;INTRAVENOUS Prescription

82. Drug name - XYREM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963 JAZZ PHARMS Sensitive drug distribution system and method Dec, 2022

(2 months from now)

Drugs and Companies using SODIUM OXYBATE ingredient

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.5GM/ML SOLUTION;ORAL Prescription

83. Drug name - XYWAV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963 JAZZ Sensitive drug distribution system and method Dec, 2022

(2 months from now)

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML SOLUTION;ORAL Prescription

84. Drug name - ZIOPTAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5886035 AKORN Difluoroprostaglandin derivatives and their use
Dec, 2022

(2 months from now)

EP850926A3 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

EP850926A2 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

EP850926B1 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

Drugs and Companies using TAFLUPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.0015% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.